A Personalized Surveillance & Intervention Protocol for Duodenal & Gastric

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of a personalized surveillance and intervention protocol for duodenal and gastric polyposis in patients with familial adenomatous polyposis (FAP)

Clinical Trial Description

Patients with FAP are not only at risk of developing colorectal adenomas but also at high risk of developing duodenal adenomas. In 30% to 92% of FAP patients duodenal adenomas are detected, with a lifetime risk approaching 100%. Of these duodenal adenomas, only a small proportion develops into duodenal cancer, with a prevalence of approximately 5-10% in FAP patients. Endoscopic surveillance is nowadays the standard of care to prevent FAP patients from developing duodenal cancer. The severity of duodenal polyposis is assessed using the Spigelman classification system. This classification is based on the number, size, histology, and grade of dysplasia of the duodenal adenomas, resulting in a score varying from 0-IV, guiding surveillance intervals and treatment. Concerns are rising on the accuracy of the Spigelman score as predictor for duodenal cancer, especially for ampullary cancer. Over the past years, multiple studies demonstrated limitations of this staging system including the fact that this classification does not adequately predict duodenal/ampullary cancer and does not guide endoscopic or surgical interventions. A clear endoscopic intervention protocol is needed, not only to prevent the development of cancer but also to prevent the need for duodenal surgery, since these surgical procedures are associated with high complication and mortality rates. With this study, the investigators aim to evaluate a personalized surveillance and intervention protocol for the duodenum and stomach with the goal to prevent the development of advanced neoplasia (AN) by endoscopically removing lesions before they progress to AN. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04677998
Study type	Observational [Patient Registry]
Source	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact
Status	Recruiting
Phase
Start date	November 24, 2020
Completion date	November 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05630794` - Testing ONC201 to Prevent Colorectal Cancer	Phase 1
Completed	`NCT02961374` - Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer	Phase 2
Completed	`NCT01483144` - Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)	Phase 3
Completed	`NCT00641147` - Curcumin in Treating Patients With Familial Adenomatous Polyposis	Phase 2
Recruiting	`NCT03471403` - Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis
Not yet recruiting	`NCT04531930` - Colorectal Adenoma Canceration in FAP
Recruiting	`NCT04678011` - A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
Completed	`NCT00927485` - Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)	N/A
Recruiting	`NCT00253812` - Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy	N/A
Withdrawn	`NCT00248053` - Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients	Phase 2
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Completed	`NCT04674228` - Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01
Completed	`NCT01656746` - Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease	N/A
Completed	`NCT00808743` - Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis	Phase 2/Phase 3
Active, not recruiting	`NCT03847636` - CryoBalloon Ablation for Treatment of Duodenal Adenomas	N/A
Not yet recruiting	`NCT05112822` - Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)	Phase 1
Recruiting	`NCT02656134` - Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)	N/A
Withdrawn	`NCT01245816` - A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)	Phase 3
Recruiting	`NCT04709445` - Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses	N/A
Enrolling by invitation	`NCT05402891` - The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms